Early detection and modern treatments make cervical cancer one of the most preventable and treatable cancers. Newport Women’s ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc (PSNL). (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study ...

Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate. The Food and Drug Administration (FDA) has granted full approval to Tivdak ® (tisotumab vedotin-tftv) for the treatment ...

Cervical cancer remains one of the most challenging diseases in oncology, with high recurrence rates and significant treatment side effects. For decades, the standard approach has relied on a ...

Cervical cancer is a serious type of cancer and its recurrence after treatment is an issue doctors want to address. Experts are interested in finding the best combination of therapies to treat ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of ...

This study, innovaTV 301, was a phase 3, multinational, open-label trial (n = 502) of tisotumab vedotin as a second- or third-line therapy compared with the investigator's choice of chemotherapy. The ...

A new computer model may be able to forecast cervical cancer recurrence in an individual based on how the tumor changes in size after the first rounds of radiation therapy, a team of researchers ...

Cervical cancer remains a significant health concern, accounting for approximately 4,000 deaths annually in the United States alone. Recent advancements in treatment strategies are crucial, especially ...

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to ...

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital ...

“We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer,” said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at ...